The U.S. Food and Drug Administration has issued warning letters to several telehealth companies regarding the sale of compounded GLP-1 weight-loss medications. These drugs have gained popularity as lower-cost alternatives to brand-name options like Ozempic and Wegovy during product shortages, but federal regulators caution that they lack the safety and efficacy standards required for FDA-approved treatments.
Compounded medications involve altered ingredients tailored for individual patients, which can change aspects like strength and delivery methods. However, doctors note that because these versions bypass rigorous regulatory oversight, patients face unknown risks. Medical professionals warn that even if the active ingredients match brand-name products, the manufacturing process for compounded alternatives is not consistent or validated for consumer safety.
While cost remains a major factor, with brand-name versions often exceeding $1,000 per month, the FDA advises against using these alternatives unless specific medical needs cannot be met through approved prescriptions. Patients are encouraged to obtain medications through legitimate channels and consult with their licensed healthcare providers to understand the potential side effects and health hazards involved with non-approved, compounded variants.
The popularity of these drugs has surged significantly, with nearly one-third of GLP-1 users obtaining their supply from compounding pharmacies two years ago. As patent protections for brand-name semaglutide products remain in place, experts emphasize the need for continued vigilance regarding the sources and quality of weight-loss drugs currently circulating in the marketplace.